Financial Reports Latest Updates Industry Maps Economic Calendar

Travere Therapeutics, Inc. (TVTX) Annual Reports

Q: Where can I read Travere Therapeutics, Inc. (TVTX) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Travere Therapeutics, Inc. is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1438533 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$169.6M	$114.4M	+48.2%
Operating income	$4.0M	$-12.7M	+131.3%
Net income	$-34.8M	$-12.8M	-172.8%
EPS (diluted)	$-0.37	$-0.14	-164.3%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 170 mn Net income -34.8 mn

Show table：Income statement

Item	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q3	2012Q4	2012Q1	2012Q2	2012Q2	2012Q3	2012Q3	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	0	0	0	0	0	0	—	0	—	0	—	0	—	0	—	—	—	—	0	0.03	5.74	8.35	14.1	17.4	24.1	28.0	30.4	29.0	33.3	34.0	37.3	33.6	38.8	40.3	42.2	38.4	41.3	40.7	43.8	39.6	44.7	44.4	46.7	47.8	48.4	51.1	51.0	47.4	54.6	68.2	57.3	48.5	54.2	53.5	29.3	57.0	59.7	37.1	45.1	41.4	54.1	62.9	74.8	81.7	114	165	130	127	170
Operating income	—	—	—	—	—	—	—	—	-3.56	—	-4.74	—	-8.46	—	-13.5	-2.25	-5.10	-5.15	-11.9	-16.9	-20.5	-23.4	-18.7	-8.10	-6.82	-20.5	-15.2	-8.24	-11.4	-20.4	-18.2	-14.4	-13.6	-10.6	-0.01	-17.9	-21.6	-35.6	-4.99	-38.2	-36.5	-34.4	-28.2	-15.1	-23.1	-19.4	-119	-47.5	-35.3	-31.7	-47.2	-66.1	-65.5	-68.1	-86.7	-87.0	-87.6	-92.6	-94.2	-139	-67.7	-56.1	-60.7	-42.7	-12.7	24.9	-32.4	-36.9	3.95
Net income	-0.01	-0.01	0	0	0	0	-3.27	-0.01	-3.57	0	-4.76	0	-8.48	0	-13.5	-4.74	-5.05	-10.9	-12.8	-70.6	8.48	-19.6	-29.0	39.6	-25.5	106	-2.47	11.2	-13.4	-37.1	-8.60	-11.1	-13.2	-17.8	-0.02	-18.4	-22.3	-54.5	-7.45	-41.0	-38.7	-36.5	-30.3	0.81	-26.1	-22.6	-122	-53.9	-39.0	-35.6	-51.6	-76.0	-67.0	-69.7	-65.8	-86.3	-85.6	151	-90.2	-136	-70.4	-54.8	-60.3	-41.2	-12.8	25.7	2.73	-37.1	-34.8

Balance sheet

Quarterly · In mn (USD)

Total assets 799 mn Total liabilities 775 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q3	2012Q4	2012Q1	2012Q2	2012Q2	2012Q3	2012Q3	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	—	—	—	—	0.02	0	—	0	—	0	—	0	0.03	2.64	0.4	16.9	7.50	6.44	53.4	45.4	37.3	234	245	300	302	298	300	343	332	322	320	325	326	287	279	503	496	476	457	440	429	407	506	498	410	565	550	579	583	631	587	535	486	605	542	686	617	481	369	325	417	374	380	371	438	393	615
Total assets	—	—	—	—	—	—	0.02	0	—	0	—	0	—	0	2.39	4.95	2.67	21.4	20.5	94.0	156	146	135	416	425	512	512	507	534	532	525	510	507	521	520	501	491	716	709	668	648	614	605	573	679	692	607	764	747	775	777	828	779	726	673	808	736	833	789	664	551	504	594	549	555	539	605	555	799
Current liabilities	—	—	—	—	—	—	0.56	0.07	—	0.07	—	0.07	—	0.07	5.80	1.22	11.1	27.2	35.2	113	48.0	49.1	108	102	172	102	85.8	66.6	80.1	86.0	83.3	76.6	79.6	83.9	85.7	56.5	104	99.9	105	104	90.6	88.0	95.5	68.1	69.9	75.4	92.7	85.0	97.0	113	124	119	124	131	142	131	136	139	178	173	121	190	201	182	190	135	160	125	152
Total liabilities	—	—	—	—	—	—	—	—	—	—	—	—	—	—	5.80	8.17	—	—	38.8	129	154	156	173	247	274	221	212	188	220	225	218	209	211	216	227	201	203	397	391	382	370	368	384	347	360	391	396	401	414	468	475	620	623	626	630	619	620	553	588	589	536	535	535	516	523	465	490	456	775
Equity	—	—	-0.06	—	—	-0.06	-0.54	-0.06	—	-0.06	—	-0.06	—	-0.06	-3.41	-3.22	-8.46	-5.80	-18.3	-35.4	1.07	-10.2	-37.3	169	151	291	300	319	314	308	308	301	296	305	293	299	288	319	318	286	277	246	221	226	319	301	211	363	332	307	302	208	157	101	42.9	189	116	280	201	74.1	15.2	-30.4	59.1	32.8	32.8	73.6	115	98.7	24.5

Cash flow

Quarterly · In mn (USD)

Operating 58.1 mn Investing -206 mn Financing 188 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q3	2012Q4	2012Q1	2012Q2	2012Q2	2012Q3	2012Q3	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	0	0	0	0	0	0	-0.79	0	-1.22	0	-0.39	0	-0.47	0	-0.65	-4.58	-2.21	-2.66	-8.15	-9.81	-11.4	-15.5	-9.09	-7.33	7.90	1.43	-3.38	-3.57	3.99	4.74	-8.61	-2.78	4.84	6.20	-0.85	-14.7	-2.76	-3.90	-3.56	-20.5	-19.1	-14.1	-4.49	-29.1	-6.45	6.74	-13.9	-26.5	6.50	32.1	-26.9	-55.3	-36.8	-39.5	-54.6	-81.1	-69.3	-59.1	-70.5	-119	-40.2	-42.5	-35.7	-42.2	4.98	14.3	60.7	-40.4	58.1
Investing	—	—	—	—	—	—	0.01	—	-0.2	—	-1.08	—	-0.29	—	3.27	-1.31	-0.01	-5.36	1.26	-31.1	-6.06	-2.06	1.97	-29.9	-1.40	51.1	-100	-9.76	-4.29	-6.17	30.6	4.13	43.8	-2.19	-0.1	-20.9	27.9	-162	-48.8	-11.4	25.2	4.47	1.58	39.5	67.8	-43.2	-126	-106	-71.8	32.5	7.37	33.2	-39.1	10.1	-36.7	-37.0	-23.6	133	-16.9	105	28.6	46.1	-80.3	41.3	4.85	86.6	-105	21.6	-206
Financing	—	—	—	—	—	—	0.81	—	1.41	—	1.50	—	0.73	—	0.79	8.38	0	21.1	-0.53	38.6	53.7	3.54	-0.53	139	1.07	-39.7	0.23	-0.93	-1.92	4.04	-6.89	-0.36	-1.39	5.84	1.36	-2.70	3.09	231	0.53	-1.11	-0.32	-0.74	0.1	-5.77	109	-0.35	25.0	196	0.3	2.41	33.2	114	0.83	2.28	0.55	217	2.27	-0.63	0.12	-0.52	0.78	0.05	139	3.72	1.48	-65.3	26.7	4.20	188
Cash at period end	—	—	—	—	—	—	0.01	—	0	—	0.03	—	0	—	0.01	2.50	0.29	13.4	6.00	3.70	39.9	25.9	18.2	120	128	141	37.8	23.3	21.2	23.9	41.0	41.9	89.3	99.0	99.4	61.1	89.3	155	103	69.8	75.7	65.2	62.4	67.0	237	200	84.8	148	83.3	150	166	257	180	151	61.7	161	70.9	144	58.2	43.3	32.3	36.4	58.5	61.9	75.2	111	93.0	78.4	118

Profitability

Quarterly · %

Operating margin 2.3% Net margin -20.5%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q3	2012Q4	2012Q1	2012Q2	2012Q2	2012Q3	2012Q3	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-60758.9%	-357.1%	-280.8%	-132.7%	-46.6%	-28.4%	-73.2%	-49.9%	-28.4%	-34.2%	-60.0%	-48.8%	-42.9%	-35.0%	-26.3%	-0.0%	-46.6%	-52.2%	-87.4%	-11.4%	-96.6%	-81.7%	-77.6%	-60.3%	-31.5%	-47.7%	-38.0%	-232.5%	-100.3%	-64.7%	-46.5%	-82.4%	-136.4%	-120.8%	-127.4%	-295.5%	-152.7%	-146.7%	-249.6%	-209.1%	-336.5%	-125.1%	-89.3%	-81.2%	-52.2%	-11.1%	15.1%	-25.0%	-29.0%	2.3%
Net margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-253138.8%	147.7%	-234.3%	-206.1%	228.3%	-106.1%	377.0%	-8.1%	38.7%	-40.2%	-109.3%	-23.1%	-33.0%	-34.1%	-44.1%	-0.0%	-47.8%	-54.0%	-133.9%	-17.0%	-103.6%	-86.6%	-82.2%	-64.8%	1.7%	-53.8%	-44.1%	-238.6%	-113.6%	-71.4%	-52.2%	-90.1%	-156.7%	-123.8%	-130.2%	-224.3%	-151.5%	-143.4%	406.4%	-200.1%	-328.9%	-130.1%	-87.1%	-80.6%	-50.4%	-11.1%	15.6%	2.1%	-29.2%	-20.5%

Returns & leverage

Quarterly · %

ROE -151.8% ROA -6.4% Debt ratio 96.9%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q3	2012Q4	2012Q1	2012Q2	2012Q2	2012Q3	2012Q3	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-0.7%	-45.4%	64.6%	89.3%	36.4%	43.4%	-14.0%	-15.8%	-22.6%	-22.9%	-16.6%	-14.0%	-16.5%	-20.1%	-30.6%	-33.6%	-42.8%	-50.1%	-43.8%	-54.3%	-40.9%	-30.9%	-28.5%	-78.4%	-76.2%	-72.8%	-82.2%	-70.2%	-70.8%	-94.2%	-129.5%	-161.5%	-145.4%	-225.1%	-45.8%	-91.4%	-122.4%	-221.7%	-281.9%	-247.4%	-424.2%	-706.0%	-410.8%	-29.4%	-32.6%	-151.8%
ROA	—	—	—	—	—	—	-16754.3%	-84167.9%	—	-175862.1%	—	-213579.7%	—	-339687.1%	-920.8%	-1080.2%	-872.8%	-320.3%	-292.8%	-200.8%	-108.5%	-113.0%	-142.0%	-0.2%	-11.9%	27.6%	36.2%	19.2%	21.0%	-8.0%	-9.2%	-13.8%	-13.4%	-9.6%	-8.1%	-9.8%	-11.7%	-15.4%	-16.7%	-21.4%	-24.9%	-18.6%	-22.3%	-16.9%	-13.9%	-11.9%	-27.9%	-33.5%	-33.3%	-34.1%	-26.0%	-25.4%	-30.2%	-35.2%	-38.4%	-35.3%	-40.6%	-11.2%	-15.2%	-21.9%	-22.7%	-52.6%	-46.5%	-37.4%	-30.6%	-17.0%	-4.3%	-3.9%	-6.4%
Debt ratio	—	—	—	—	—	—	—	—	—	—	—	—	—	—	242.5%	165.1%	—	—	189.3%	137.6%	99.3%	107.0%	127.5%	59.5%	64.5%	43.1%	41.5%	37.0%	41.1%	42.2%	41.4%	41.0%	41.7%	41.5%	43.7%	40.2%	41.4%	55.5%	55.1%	57.2%	57.2%	59.9%	63.4%	60.6%	53.0%	56.5%	65.2%	52.5%	55.5%	60.3%	61.1%	74.9%	79.9%	86.1%	93.6%	76.6%	84.2%	66.4%	74.5%	88.8%	97.3%	106.0%	90.1%	94.0%	94.1%	86.3%	81.0%	82.2%	96.9%

EPS

Quarterly · US$

EPS US$-0.37

Show table：EPS

Item	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q3	2012Q4	2012Q1	2012Q2	2012Q2	2012Q3	2012Q3	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-0.41	-0.71	-0.82	-3.25	-0.90	-0.89	-1.10	1.32	-0.73	1.78	-0.14	-0.08	-0.37	-1.00	-0.39	-0.32	-0.34	-0.46	-0.55	-0.46	-0.56	-1.34	-0.18	-0.99	—	—	-2.47	0.02	-0.58	-0.44	-2.53	-0.96	-0.64	-0.59	-0.84	-1.20	-1.05	-1.09	-1.03	-1.27	-1.13	1.97	-1.18	-1.76	-0.91	-0.70	-0.71	-0.47	-0.14	0.28	0.03	-0.40	-0.37

Revenue & profit

Year-to-date · In mn (USD)

Revenue 297 mn Net income -71.9 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 799 mn Total liabilities 775 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating 17.7 mn Investing -185 mn Financing 192 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin -11.1% Net margin -24.2%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -151.8% ROA -6.4% Debt ratio 96.9%

EPS

Year-to-date · US$

EPS US$-0.77

Revenue & profit

Annual · In mn (USD)

Revenue 491 mn Net income -25.6 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2012	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	—	28.2	99.9	134	155	164	175	198	227	185	199	233	491
Operating income	—	-79.6	-50.6	-58.2	-38.6	-80.0	-137	-176	-162	-286	-361	-324	-62.8
Net income	-33.6	-111	117	-47.9	-42.1	-103	-146	-169	-180	-278	-111	-322	-25.6

Balance sheet

Annual · In mn (USD)

Total assets 605 mn Total liabilities 490 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2012	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	0	37.3	302	332	326	496	429	410	583	486	617	417	438
Total assets	0	135	512	525	520	709	605	607	777	673	789	594	605
Current liabilities	0.07	108	85.8	83.3	85.7	105	95.5	92.7	124	142	178	201	160
Total liabilities	—	173	212	218	227	391	384	396	475	630	588	535	490
Equity	-0.06	-37.3	300	308	293	318	221	211	302	42.9	201	59.1	115

Cash flow

Annual · In mn (USD)

Operating 37.8 mn Investing 27.9 mn Financing -33.5 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2012	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	-3.52	-45.9	-1.39	-3.44	7.40	-25.0	-58.2	-42.7	-14.8	-186	-280	-237	37.8
Investing	—	-37.3	-80.6	10.4	45.6	-203	19.9	-61.3	-138	-32.5	55.8	99.3	27.9
Financing	—	95.3	101	-5.69	5.45	232	-2.08	128	232	118	219	139	-33.5
Cash at period end	—	18.2	37.8	41.0	99.4	103	62.4	84.8	166	61.7	58.2	58.5	93.0

Profitability

Annual · %

Operating margin -12.8% Net margin -5.2%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2012	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	—	-282.2%	-50.7%	-43.6%	-24.9%	-48.7%	-78.3%	-88.8%	-71.1%	-154.4%	-181.8%	-138.9%	-12.8%
Net margin	—	-392.6%	117.4%	-35.9%	-27.2%	-62.5%	-83.5%	-85.4%	-79.2%	-150.1%	-56.0%	-137.9%	-5.2%

Returns & leverage

Annual · %

ROE -29.4% ROA -4.3% Debt ratio 81.0%

Show table：Returns & leverage

Item	2012	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	—	—	89.3%	-15.8%	-14.0%	-33.6%	-54.3%	-78.4%	-70.2%	-161.5%	-91.4%	-247.4%	-29.4%
ROA	-860787.3%	-163.5%	36.2%	-9.2%	-8.1%	-16.7%	-22.3%	-27.9%	-26.0%	-38.4%	-15.2%	-46.5%	-4.3%
Debt ratio	—	127.5%	41.5%	41.4%	43.7%	55.1%	63.4%	65.2%	61.1%	93.6%	74.5%	90.1%	81.0%

EPS

Annual · US$

EPS US$-0.30

Show table：EPS

Item	2012	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	-6.14	2.23	-1.84	-1.67	-2.54	—	-3.53	-3.03	-4.37	-1.61	-4.08	-0.30

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Travere Therapeutics, Inc. (TVTX) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.